BRIEF-OSE Immunotherapeutics Presents Positive OSE-172 Human Ex-Vivo And Preclinical Study Results
March 19 (Reuters) - OSE IMMUNOTHERAPEUTICS SA:
* TO PRESENT NEW DATA ON OSE-172 AT AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING
* ‍OSE-172, SIRPA ANTAGONIST, PREVENTS METASTASIS SPREAD IN AGGRESSIVE CANCER MODELS​
* OSE-172 ‍DECREASES TUMOR GROWTH AND SUPPRESSIVE FUNCTION OF TUMOR MYELOID CELLS
* ‍OSE-172 POTENTIATES DENDRITIC CELL TUMOR ANTIGEN CROSS-PRESENTATION INCREASING T-CELL SPECIFIC ACTIVATION​
* ‍DATA BEING PRESENTED ON OSE-172 INCLUDE RESULTS FROM HUMAN EX-VIVO AND PRECLINICAL STUDIES​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)